title: Encephalophaty associated with rasagiline and sertraline in Parkinson's disease: possible serotonin syndrome.
authors.affiliation: Service de Neurologie, CHU Bordeaux, Pessac, France.
authors.forename: Fanny
authors.initials: F
authors.lastname: Duval
authors.forename: Olivier
authors.initials: O
authors.lastname: Flabeau
authors.forename: Julien
authors.initials: J
authors.lastname: Razafimahefa
authors.forename: Umberto
authors.initials: U
authors.lastname: Spampinato
authors.forename: François
authors.initials: F
authors.lastname: Tison
mesh_terms: D000368:Aged; D017109:Akathisia, Drug-Induced / Q000503:physiopathology; D000978:Antiparkinson Agents / Q000627:therapeutic use; D001927:Brain Diseases / Q000209:etiology*; D003702:Delusions / Q000139:chemically induced; D003865:Major Depressive Disorder / Q000150:complications / Q000188:drug therapy; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007189:Indans / Q000009:adverse effects* / Q000627:therapeutic use; D009207:Myoclonus / Q000139:chemically induced / Q000503:physiopathology; D018696:Neuroprotective Agents / Q000009:adverse effects* / Q000627:therapeutic use; D010300:Parkinson Disease / Q000150:complications* / Q000188:drug therapy; D020230:Serotonin Syndrome / Q000209:etiology* / Q000503:physiopathology; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D020280:Sertraline / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000978:Antiparkinson Agents; D007189:Indans; D018696:Neuroprotective Agents; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline; C031967:rasagiline